SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 0.00 |
| Book Value / Share | n/a |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | n/a |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.00 |
| Assets | 0.00 |
| Liabilities | 0.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| SCHEDULE 13D | AIX Inc. | |||
| 13D | LX Management Co Ltd | 49.00 | ||
| 13D/A | Ahanzhai Development Ltd | 38.30 | 78.82 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,129 | 20,014 | 5.64 | |
| 14,704 | 92,150 | 15.96 | |
| 10,254 | 81,687 | 12.55 | |
| 14,223 | 202,916 | 7.01 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BCTX – BriaCell Therapeutics Corp. | BFRG – Bullfrog AI Holdings, Inc. |
| BFRI – Biofrontera Inc. | BIVI – BioVie Inc. |
| BMRA – Biomerica, Inc. |
Financial data and stock pages provided by
Fintel.io